Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet_老虎社区_美港股上老虎

Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet

Tiger Newspress2021-08-02

(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.

"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial," said Andrei Floroiu, CEO of Vaxart.

The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.

Vaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

128

Kaboom
·2021-08-03
What’s IND?
回复
1
举报
ASMH
·2021-08-03
Like
回复
2
举报
收起
- Singman:
  like too.
  2021-08-03
  回复
  举报
- ASMH:
  Like
  2021-08-04
  回复
  举报
- Loola:
  like
  2021-08-10
  回复
  举报
查看更多 1 条评论
Astlen
·2021-08-03
Cool
回复
1
举报
晓MIIN
·2021-08-03
👀
回复
3
举报
Esha
·2021-08-03
Good jump. 😄😄😄
回复
2
举报
YYKTAN
·2021-08-03
Like pls
回复
5
举报
tianzi
·2021-08-03
Nice sharing
回复
2
举报
Jasmineding
·2021-08-03
Good
回复
1
举报
Kennypang92
·2021-08-03
Ok
回复
3
举报
AmosOng
·2021-08-02
Nice
回复
4
举报
OO_898
·2021-08-02
Like
回复
7
举报
MrGuHHH
·2021-08-02
ok
回复
4
举报
收起
- Benedict_cyh:
  N
  2021-08-03
  回复
  举报
markkk
·2021-08-02
nice
回复
3
举报
PanaCota
·2021-08-02
Ok
回复
3
举报
PanaCota
·2021-08-02
Ok
回复
3
举报
KailashN
·2021-08-02
Good! Like please
回复
4
举报
Redevilz
·2021-08-02
Go higher please
回复
5
举报
收起
- Cyberboyz:
  Yeah
  2021-08-04
  回复
  举报
Money99
·2021-08-02
Good
回复
6
举报
收起
- Cyberboyz:
  Yes
  2021-08-04
  回复
  举报
blackmetal
·2021-08-02
Leave one comment
回复
3
举报
收起
- KailashN:
  Done
  2021-08-02
  回复
  举报
- El888:
  Same
  2021-08-02
  回复
  举报
- markkk:
  bice
  2021-08-02
  回复
  举报
aiyohyun
·2021-08-02
Ok
回复
3
举报
收起
- aiyohyun:
  ok
  2021-08-02
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1164080452?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-02 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164080452","market":"us","top_or_hot":-1,"title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","media":"Tiger Newspress","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-02 22:38 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc","start_time":0,"source_url":null,"article_id":"1164080452","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","pubTimestamp":1627915085,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc"},"translate_title":"美国食品和药物管理局批准口服新冠肺炎疫苗片剂后，Vaxart股价上涨超过8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":807357178,"gmtCreate":1628002222894,"gmtModify":1631890403024,"author":{"id":"3573515033218465","authorId":"3573515033218465","authorIdStr":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573515033218465"},"htmlText":"What’s IND?","listText":"What’s IND?","text":"What’s IND?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807357178","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804173208,"gmtCreate":1627947986004,"gmtModify":1633755083205,"author":{"id":"3586939439858903","authorId":"3586939439858903","authorIdStr":"3586939439858903","name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586939439858903"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/804173208","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5407635,"gmtCreate":1627948381235,"gmtModify":1635161628898,"authorId":3575125836760247,"author":{"id":3575125836760247,"authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":0,"prevId":0,"content":"like too.","text":"like too.","html":"like too."},{"id":5419343,"gmtCreate":1628037652447,"gmtModify":1635160706854,"authorId":3586939439858903,"author":{"id":3586939439858903,"authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":5407635,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":5483578,"gmtCreate":1628597842419,"gmtModify":1635155228839,"authorId":3577872621107081,"author":{"id":3577872621107081,"authorId":3577872621107081,"name":"Loola","avatar":"https://static.tigerbbs.com/64940dfb0e60ec6f7fff49d64ddfc53a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"},{"id":5487592,"gmtCreate":1628637348194,"gmtModify":1635154908482,"authorId":3586939439858903,"author":{"id":3586939439858903,"authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":5483578,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"EN"},{"id":804143403,"gmtCreate":1627947493802,"gmtModify":1631892583545,"author":{"id":"3585883817320380","authorId":"3585883817320380","authorIdStr":"3585883817320380","name":"Astlen","avatar":"https://static.tigerbbs.com/74d3365b9fec276d23866d035ec56152","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585883817320380"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804143403","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804156415,"gmtCreate":1627947238837,"gmtModify":1633755099194,"author":{"id":"3573767135380290","authorId":"3573767135380290","authorIdStr":"3573767135380290","name":"晓MIIN","avatar":"https://static.tigerbbs.com/9e223a6a40d05afa03fb58b646e13cd1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573767135380290"},"htmlText":"👀","listText":"👀","text":"👀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804156415","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804165775,"gmtCreate":1627946436097,"gmtModify":1633755116464,"author":{"id":"3578623735089935","authorId":"3578623735089935","authorIdStr":"3578623735089935","name":"Esha","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3578623735089935"},"htmlText":"Good jump. 😄😄😄","listText":"Good jump. 😄😄😄","text":"Good jump. 😄😄😄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804165775","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804184714,"gmtCreate":1627945912338,"gmtModify":1633755125470,"author":{"id":"3586858995147972","authorId":"3586858995147972","authorIdStr":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586858995147972"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804184714","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804352826,"gmtCreate":1627939200865,"gmtModify":1633755191478,"author":{"id":"4088786948347050","authorId":"4088786948347050","authorIdStr":"4088786948347050","name":"tianzi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088786948347050"},"htmlText":"Nice sharing","listText":"Nice sharing","text":"Nice sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804352826","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804337717,"gmtCreate":1627921180139,"gmtModify":1633755224181,"author":{"id":"3570431728680943","authorId":"3570431728680943","authorIdStr":"3570431728680943","name":"Jasmineding","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570431728680943"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804337717","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804330613,"gmtCreate":1627920441432,"gmtModify":1633755231342,"author":{"id":"4087263927700590","authorId":"4087263927700590","authorIdStr":"4087263927700590","name":"Kennypang92","avatar":"https://static.tigerbbs.com/be100a8f75ff1601b99932f9128063af","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087263927700590"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804330613","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804971436,"gmtCreate":1627918595125,"gmtModify":1633755249550,"author":{"id":"4089419582580250","authorId":"4089419582580250","authorIdStr":"4089419582580250","name":"AmosOng","avatar":"https://static.tigerbbs.com/fba31698cfe7796a86f6ea286063390f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089419582580250"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804971436","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804942702,"gmtCreate":1627918271706,"gmtModify":1633755253038,"author":{"id":"3582969710070724","authorId":"3582969710070724","authorIdStr":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582969710070724"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804942702","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804949545,"gmtCreate":1627917948787,"gmtModify":1633755255950,"author":{"id":"3585044989004914","authorId":"3585044989004914","authorIdStr":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585044989004914"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804949545","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5406182,"gmtCreate":1627927713621,"gmtModify":1635161761797,"authorId":3581667328055955,"author":{"id":3581667328055955,"authorId":3581667328055955,"name":"Benedict_cyh","avatar":"https://static.tigerbbs.com/216a5cf2e56f81472309860a063b75a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804949545,"type":1,"supId":0,"prevId":0,"content":"N","text":"N","html":"N"}],"langContent":"EN"},{"id":804954011,"gmtCreate":1627917744333,"gmtModify":1633755258189,"author":{"id":"3576420733683738","authorId":"3576420733683738","authorIdStr":"3576420733683738","name":"markkk","avatar":"https://static.tigerbbs.com/df42d8e8fb0e4c7a09fcf6592b170a1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576420733683738"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804954011","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804951717,"gmtCreate":1627917564839,"gmtModify":1633755261473,"author":{"id":"3581588474178431","authorId":"3581588474178431","authorIdStr":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804951717","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804951682,"gmtCreate":1627917555846,"gmtModify":1633755261800,"author":{"id":"3581588474178431","authorId":"3581588474178431","authorIdStr":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804951682","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804926070,"gmtCreate":1627917228390,"gmtModify":1631892185862,"author":{"id":"3582703680193232","authorId":"3582703680193232","authorIdStr":"3582703680193232","name":"KailashN","avatar":"https://static.tigerbbs.com/bcea4d0815f5091810e222c8e9e54c35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582703680193232"},"htmlText":"Good! Like please","listText":"Good! Like please","text":"Good! Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804926070","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804921906,"gmtCreate":1627917123105,"gmtModify":1633755269268,"author":{"id":"3562980680046161","authorId":"3562980680046161","authorIdStr":"3562980680046161","name":"Redevilz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562980680046161"},"htmlText":"Go higher please","listText":"Go higher please","text":"Go higher please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804921906","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5426621,"gmtCreate":1628086906556,"gmtModify":1635160166795,"authorId":3583025625698124,"author":{"id":3583025625698124,"authorId":3583025625698124,"name":"Cyberboyz","avatar":"https://static.tigerbbs.com/bda6a2e3c6fe5eaf97f2228f49f8e497","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804921906,"type":1,"supId":0,"prevId":0,"content":"Yeah","text":"Yeah","html":"Yeah"}],"langContent":"EN"},{"id":804989502,"gmtCreate":1627916049406,"gmtModify":1633755285094,"author":{"id":"3581545542045651","authorId":"3581545542045651","authorIdStr":"3581545542045651","name":"Money99","avatar":"https://static.tigerbbs.com/f333c4a87fea0043f4483c465362baf9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3581545542045651"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804989502","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5426622,"gmtCreate":1628086915818,"gmtModify":1635160166671,"authorId":3583025625698124,"author":{"id":3583025625698124,"authorId":3583025625698124,"name":"Cyberboyz","avatar":"https://static.tigerbbs.com/bda6a2e3c6fe5eaf97f2228f49f8e497","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804989502,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":804980773,"gmtCreate":1627916011292,"gmtModify":1631883895454,"author":{"id":"3576318339568790","authorId":"3576318339568790","authorIdStr":"3576318339568790","name":"blackmetal","avatar":"https://static.tigerbbs.com/fcf35b941f4aacd314b36e1f1d2b9bc5","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3576318339568790"},"htmlText":"Leave one comment","listText":"Leave one comment","text":"Leave one comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/804980773","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5405243,"gmtCreate":1627917271135,"gmtModify":1635161826623,"authorId":3582703680193232,"author":{"id":3582703680193232,"authorId":3582703680193232,"name":"KailashN","avatar":"https://static.tigerbbs.com/bcea4d0815f5091810e222c8e9e54c35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5405286,"gmtCreate":1627917453870,"gmtModify":1635161822936,"authorId":3574042378067249,"author":{"id":3574042378067249,"authorId":3574042378067249,"name":"El888","avatar":"https://static.tigerbbs.com/9ae2260d0c9fcfaa0627f13d75da54b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":0,"prevId":0,"content":"Same","text":"Same","html":"Same"},{"id":5405347,"gmtCreate":1627917739413,"gmtModify":1635161818799,"authorId":3576420733683738,"author":{"id":3576420733683738,"authorId":3576420733683738,"name":"markkk","avatar":"https://static.tigerbbs.com/df42d8e8fb0e4c7a09fcf6592b170a1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":5405286,"prevId":0,"content":"bice","text":"bice","html":"bice"}],"langContent":"EN"},{"id":804980946,"gmtCreate":1627915950785,"gmtModify":1633755286543,"author":{"id":"3582936698066263","authorId":"3582936698066263","authorIdStr":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582936698066263"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804980946","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://www.laohu8.com/m/news/1164080452?lang=&edition=full","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5405010,"gmtCreate":1627915979170,"gmtModify":1635161845797,"authorId":3582936698066263,"author":{"id":3582936698066263,"authorId":3582936698066263,"name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980946,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":128,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}